DCVAC/LuCa
Alternative Names: Dendritic cell vaccine/Lung cancer - SotioLatest Information Update: 20 May 2022
At a glance
- Originator SOTIO
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 01 Nov 2021 Sotio completes a phase I/II trial in Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in Slovakia (SC) (NCT02470468)
- 03 Jun 2019 Updated adverse events and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
- 03 Jun 2018 Efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)